BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:HLX15 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of HLX15\, from ClinicalTrials.gov estimates
 .
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07477587-3168@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20270525
DTEND;VALUE=DATE:20270526
SUMMARY:HLX15: Phase 1 readout est. (NCT07477587)
DESCRIPTION:HLX15\, phase 1\, Multiple Myeloma.\nStudy: A Study to Compare 
 the PK Characteristics\, Safety\, Tolerability\, and Immunogenicity of HLX
 15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexameth
 asone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple
  Myeloma\nEstimated primary completion: 25 May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/hlx15#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07477587
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06895512-3168@assetmemo.bio
DTSTAMP:20261121T005851Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:HLX15: Phase 3 readout est. (NCT06895512)
DESCRIPTION:HLX15\, phase 3\, Multiple Myeloma.\nStudy: A Study to Evaluate
  the Efficacy and Safety of HLX15-IV Versus DARZALEX® in Combination with
  Lenalidomide-Dexamethasone (Rd) in Transplant-ineligible Patients with Ne
 wly Diagnosed Multiple Myeloma\nEstimated primary completion: July 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/hlx15#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT06895512
URL:https://assetmemo.bio/drug/hlx15#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
